Cabometyx (cabozantinib) offers efficacy benefits in combination with Bristol Myers Squibb’s Opdivo (nivolumab) versus sunitinib for patients with previously untreated advanced renal cell carcinoma, regardless of prior nephrectomy status, according to data from a post-hoc exploratory analysis of the phase III CheckMate -9ER pivotal trial.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
